ThromboGenics selects MSD Biologics as Microplasmin production partner
Microplasmin, ThromboGenics’ lead drug candidate, is a truncated form of the natural human protein plasmin. ThromboGenics has recently concluded two Phase III trials of Microplasmin, assessing the patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.